In the first M&A case, Star Medical acquired an unlisted company. The purchaser is a medical agent dealer, and M&A aims to be a company that researches, develops, produces and sells medical devices with its own patented technology. The transaction is a 100% equity acquisition, with a particularly high cash payment ratio of 359 million, of which only 9% has equity consideration.

In the second case, Tianshan Bio, a listed company, bought shares in elephant, which was relatively large in scale and mainly used for outdoor advertising, but the advertising form was more traditional. The total transaction amount is 2.372 billion yuan, of which more than 500 million yuan is paid in cash, and the remaining 654.38+08 billion yuan is paid in shares. At the same time, it raised 599 million matching funds.

In the third case, Tianze Company acquired Youshu. The target company is mainly engaged in cross-border e-commerce import and export, and has rich experience in logistics and supply chain, especially import and export. The profit is greater than the acquisition strategy. The entire target transaction volume is 3.4 billion, and the performance commitment is very high, adding up to 960 million. All of them paid 420 million in cash and nearly 3 billion in shares.